Sedat Karabulut

Dr. Sedat Karabulut

Nursing, University of Windsor, Windsor, Ontario, Canada
+1
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2014 in Journal of the Science of Food and Agriculture
Verified
Journal Article
Closed access
PDF file
SKSedat Karabulut
Sedat Karabulut
GPGuvanchmyrat Paytakov
Guvanchmyrat Paytakov
JLJerzy Leszczynski
Jerzy Leszczynski

1 November 2016 in Journal of Molecular Graphics and Modelling
Verified
Journal Article
Closed access
SKSedat Karabulut
Sedat Karabulut
Natalia SizochenkoNatalia Sizochenko
Natalia Sizochenko
AOAdnan Orhan
Adnan Orhan
JLJerzy Leszczynski
Jerzy Leszczynski

5 August 2009 in Journal of Coordination Chemistry
Verified
Journal Article
Closed access
CKCanan Kazak
Canan Kazak
NAN. Burcu Arslan
N. Burcu Arslan
SKSedat Karabulut
Sedat Karabulut
AAA. Dılek Azaz
A. Dılek Azaz
HNHılmı Namlı
Hılmı Namlı
RKRaıf Kurtaran
Raıf Kurtaran
The complex of 2,6-diacetylpyridinedihydrazone (L) with lead(II) and azide has been characterized by elemental analyses, FTIR, and single-crystal X-ray analysis. The Pb(C9H13N11) (1) crystallized in the monoclinic space group C2/c. The coordination of 1 exhibits a gap around the lead(II), possibly occupied by a stereochemically active electron lone pair on lead(II) resulting in a hemidirected complex. Antimicrobial activity of the complex is higher than the free ligand.

12 June 2013 in Journal of Molecular Modeling
Verified
Journal Article
Closed access
PDF file
SKSedat Karabulut
Sedat Karabulut
JLJerzy Leszczynski
Jerzy Leszczynski

7 February 2007 in Transition Metal Chemistry
Verified
Journal Article
Closed access
PDF file
HNHilmi Namli
Hilmi Namli
AAAyse Dilek Azaz
Ayse Dilek Azaz
SKSedat Karabulut
Sedat Karabulut
SÇSelma Çelen
Selma Çelen
RKRaif Kurtaran
Raif Kurtaran
CKCanan Kazak
Canan Kazak

13 September 2023 in Psychedelic Medicine
Verified
Journal Article
Closed access
HKHarpreet Kaur
Harpreet Kaur
SKSedat Karabulut
Sedat Karabulut
JGJames W. Gauld
James W. Gauld
SFStephen A. Fagot
Stephen A. Fagot
KHKalee N. Holloway
Kalee N. Holloway
WFWilliam E. Fantegrossi
William E. Fantegrossi
Autism spectrum disorder (ASD) encompasses a range of neurodevelopmental syndromes diagnostically characterized by deficits in social communication and social interaction and repetitive, inflexible patterns of behaviors, interests, and thoughts. ASD affects people worldwide, irrespective of race, ethnicity, or socio-economic status, with debilitating effects on employment and interpersonal relationships. Though the atypical antipsychotics aripiprazole and risperidone are approved to treat irritability associated with ASD, these drugs may elicit treatment-limiting adverse effects, such as suicidal ideation, sedation, diarrhea, loss of appetite, dizziness, and weight gain. However, there are no approved pharmacotherapeutics for global symptoms of ASD, and better treatments are needed. Drugs with pro-social effects, such as 3,4-methylenedioxymethamphetamine (MDMA) and its analogues, may be beneficial here, as social anxiety and social avoidance are major complications of ASD that adversely impact the quality of life for sufferers and caregivers. This review describes the complex pharmacology of methylenedioxy amphetamine analogues (hereafter referred to as MDXX drugs), focusing on MDMA and 3,4-methylenedioxy-N-methyl-α-ethylphenylethylamine (MBDB) and how they may help treat ASD. Specifically, we address the roles of various drug-binding sites, metabolic enzymes, and chemical structure-activity relationships that mediate these substances' pharmacological and toxicological effects. Throughout the review, we emphasize the distinct profiles of individual stereoisomers of the MDXX drugs and how combining these enantiomers as racemic mixtures may explain the complexity of drug effects on behavior and physiology. We propose that the MDXX drugs represent a fruitful chemical space for developing clinically effective and relatively safer molecules and formulations for treating ASD.